Details for Patent: 9,763,885
✉ Email this page to a colleague
Which drugs does patent 9,763,885 protect, and when does it expire?
Patent 9,763,885 protects ROSZET and is included in one NDA.
This patent has eleven patent family members in ten countries.
Summary for Patent: 9,763,885
| Title: | Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases |
| Abstract: | The present invention is an orally consumed fixed combination formulation of both rosuvastatin and ezetimibe in one tablet that is expected to have the same Area Under Curve as two active ingredients taken together individually orally, and pharmaceutically acceptable additives suitable for the preparation. In preferred embodiments of this invention, the rosuvastatin is in the form of rosuvastatin calcium and the pharmaceutically acceptable additives are selected from diluents, disintegrants, glidants, lubricants, colorants and combinations thereof. |
| Inventor(s): | Dias; Marie Charmaine (Morristown, NJ) |
| Assignee: | Althera Laboratories Ltd. (Dublin, IE) |
| Application Number: | 14/350,905 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; Dosage form; |
Drugs Protected by US Patent 9,763,885
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Althera Pharms | ROSZET | ezetimibe; rosuvastatin calcium | TABLET;ORAL | 213072-001 | Mar 23, 2021 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | TREATMENT OF HYPERLIPIDEMIA | ⤷ Sign Up | |||
| Althera Pharms | ROSZET | ezetimibe; rosuvastatin calcium | TABLET;ORAL | 213072-002 | Mar 23, 2021 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | TREATMENT OF HYPERLIPIDEMIA | ⤷ Sign Up | |||
| Althera Pharms | ROSZET | ezetimibe; rosuvastatin calcium | TABLET;ORAL | 213072-003 | Mar 23, 2021 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | TREATMENT OF HYPERLIPIDEMIA | ⤷ Sign Up | |||
| Althera Pharms | ROSZET | ezetimibe; rosuvastatin calcium | TABLET;ORAL | 213072-004 | Mar 23, 2021 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | TREATMENT OF HYPERLIPIDEMIA | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 9,763,885
| PCT Information | |||
| PCT Filed | May 01, 2013 | PCT Application Number: | PCT/US2013/039018 |
| PCT Publication Date: | November 07, 2013 | PCT Publication Number: | WO2013/166117 |
International Family Members for US Patent 9,763,885
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Cyprus | 1123091 | ⤷ Sign Up | |||
| Denmark | 2844233 | ⤷ Sign Up | |||
| European Patent Office | 2844233 | ⤷ Sign Up | |||
| Spain | 2802252 | ⤷ Sign Up | |||
| Hungary | E052300 | ⤷ Sign Up | |||
| Mexico | 2014013241 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
